Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2019
Reporting Period: Second fiscal quarter ended June 30, 2019, and the first half of 2019.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that the Company announced its results via a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2), which are incorporated by reference but not detailed within the body of this specific document.
Material Changes
No material changes or comparative financial data are disclosed in the text of this filing. The document references the announcement of Q2 and H1 2019 results but does not quantify changes versus prior periods.
Guidance, Outlook, and Risks
- Disclosure: The filing includes a Regulation FD disclosure regarding a corporate presentation used at industry conferences.
- Forward-Looking Statements: The Company disclaims any obligation to correct or update the information in the attached corporate presentation in the future.
- Legal Status: The press release and presentation are furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor are they incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 and H1 2019 revenue, net income, and cash flow figures.
- Examine Exhibit 99.2 (Corporate Presentation) for management commentary, strategic outlook, and operational metrics.
- Verify the Company's status as an Emerging Growth Company (indicated as checked in the filing) and its implications for financial reporting standards.
- Confirm the trading symbol ORGO on the Nasdaq Capital Market.